Oura Ring users may get in-app access to real doctors soon – what we know

Oura has entered into an agreement to acquire Counsel Health, an AI primary care company that was already a partner inside the Oura app, for $625 million. The deal is expected to close by the end of the year, according to the company. Oura frames the move as part of its shift from selling a sleep-tracking ring toward what CEO Tom Hale calls "a doctor in your pocket."
Under the arrangement, Oura users would gain access to Counsel Health's in-house physicians and its 24/7 medical AI. The two companies already work together: Oura monitors biometric data around the clock to spot deviations from a user's personal baseline, and the existing partnership layers clinical guidance on top of those signals. The acquisition is meant to deepen that by connecting members with medical AI and physicians to address timely health problems and provide support, including what the announcement described as prescriptions for episodic health conditions.
The combined offering is also positioned around specialty and chronic care, with the announcement citing reproductive, aging and cardiometabolic-related conditions as areas of focus. David Shuman, Oura's executive chairman, described the logic as complementary: Oura tells members what is happening in their bodies, and Counsel helps them act on it. He said the combination expands Oura's addressable market and deepens the value delivered to each member.
This is Oura's third acquisition this year. Earlier deals brought in Galen AI, a conversational and personal health platform that connects smart ring data to medical records, and Doublepoint AI, an AI-driven biometric and gesture recognition company whose technology could add voice or gesture controls to a future Oura ring. Read together, the three purchases point in different directions: Galen toward integrating ring data with the formal medical record, Doublepoint toward new input methods for the hardware, and Counsel toward delivering actual clinical care through the app.
One commercial question is unresolved. It is not yet known whether access to Counsel Health's physicians or the 24/7 medical AI will be included in an Oura app subscription or priced separately. Because the deal has not closed, the question may not be settled for some time. For a company whose hardware is sold alongside a recurring membership, the answer shapes both the economics and how broadly the feature reaches existing users.
What the ring actually contributes is continuous biometric data. Oura's pitch is that its sensors can flag a developing illness or a meaningful deviation from a user's baseline, such as a raised resting heart rate or elevated body temperature, before the person feels symptoms. That kind of early signal is useful but ambiguous on its own: a spike could mean many things. This is where Counsel's physicians and medical AI come in. In practice, the ring supplies the observation and the clinical layer supplies interpretation and next steps. The technical question for developers is how those handoffs work: what data flows from the ring into Counsel's systems, how clinical recommendations are generated and reviewed, and where a human physician sits in the loop. Those details are not covered by the announcement.
Oura is not alone in moving this way. Samsung announced a similar acquisition last year of Xealth, a care platform connecting more than 500 hospitals with 70 digital health centers. Praveen Raja, Samsung's VP of digital health, described the move as furthering Samsung's mission to connect the healthcare landscape, from symptom detection through to connecting patients with care providers. The pattern is that wearable makers are pushing past measurement into the delivery of care, which brings regulatory, clinical and liability questions that a step counter never raised.
A likely trade-off is breadth versus depth. A ring can spot a deviation from baseline continuously, but an in-app physician consult is episodic, and any prescription carries real-world requirements around licensing, jurisdiction and clinical standards. How far Oura takes prescribing, and in which markets, will determine whether this reads as convenient triage or as a genuine alternative to a primary care visit. The framing in the announcement, which pairs prescriptions with "episodic" conditions, suggests a narrower scope rather than ongoing primary care.
Why it matters: For product teams in wearables and digital health, this is a signal that the competitive ground is shifting from sensor accuracy and app insights toward owning the clinical layer, which means data integration, physician networks and compliance become core product concerns rather than partnerships. Developers building on Oura's ecosystem should expect the app to evolve from a data dashboard into a care interface, with new data flows and consent requirements to plan for. If the model works, it could reduce reliance on urgent care and primary care visits for minor or episodic issues, though that is an inference about the eventual outcome, not something the companies have promised.
Based on reporting from the original publisher. Visit the source for full context and later updates.
Publisher excerpt
Oura’s acquisition of Counsel Health could signal a new dawn for digital care.